查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2048359

醫療領域冷等離子體市場－全球產業規模、佔有率、趨勢、機會和預測：按應用、地區和競爭格局分類，2021-2031年

Cold Plasma in Healthcare Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Wound Healing, Surgical Application and Other Medical Applications), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球醫用冷等離子市場預計將從 2025 年的 25.9 億美元成長到 2031 年的 53.3 億美元，複合年成長率為 12.78%。

醫療領域的冷等離子體是一種在接近室溫下產生的非熱、部分電離氣體，已在消毒、慢性傷口癒合和癌症治療等領域廣泛應用，且不會對活體組織造成熱損傷。該市場的主要驅動力源於對非侵入性治療方法日益成長的需求，以及對抗抗藥性病原體對先進感染控制技術的迫切需求。尤其值得注意的是，預計到2025年，全球約有十分之一的人口將患有醫療相關感染，因此，工業界對冷等離子體等高效消毒技術的需求極為旺盛。

市場概覽
預測期 2027-2031
市場規模：2025年 25.9億美元
市場規模：2031年 53.3億美元
複合年成長率：2026-2031年 12.78%
成長最快的細分市場 創傷治療
最大的市場 北美洲

市場促進因素

慢性傷口和糖尿病潰瘍的日益普遍是推動市場擴張的主要因素，凸顯了超越傳統創傷護理的先進治療方法的必要性。冷等離子體設備正被擴大應用於促進組織再生和清除難癒合病變中的細菌生物膜，其原理是透過產生活性氧和活性氮。這項需求主要源自於全球代謝性疾病負擔的加重，預計到2025年，全球將有約5.89億成年人患有糖尿病。糖尿病與發生複雜性足部潰瘍的高風險密切相關。標準抗生素在傷口管理中的療效下降進一步加劇了此類替代療法的緊迫性。世界衛生組織（WHO）在2025年10月報告稱，自2018年以來，在監測的病原體和抗生素組合中，抗生素抗藥性增加了40%以上，這凸顯了工業界對冷等離子體技術這種非藥物滅菌機制的需求。同時，隨著冷等離子體作為選擇性癌症治療方法的潛力逐漸顯現，該市場也正在經歷顯著成長。與傳統放射線治療和化療不同，大氣壓力冷等離子體可透過氧化壓力誘導惡性細胞凋亡，且不會損傷健康組織，這代表了一種治療固態腫瘤的突破性方法。這種臨床療效已開始在監管和臨床試驗結果中得到體現。例如，2024年5月，Medical Innovations公司報告了一項使用FDA已通過核准的Canady Helios冷等離子體系統的I期臨床試驗，結果顯示，在進行性固態腫瘤患者中，非局部復發率高達80%。隨著這些積極結果不斷得到進一步研究的支持，預計等離子體系統在外科腫瘤治療方案中的應用將推動對先進電外科發生器和探針的大量投資。

市場挑戰

嚴格的醫療設備核准法規結構對全球醫用冷等離子市場構成重大障礙。這項挑戰透過設定高入門門檻阻礙市場成長，尤其對那些往往是等離子體技術創新主導的中小企業（SME）造成了不成比例的影響。檢驗部分電離氣體應用的安全性和有效性需要耗費大量資金的臨床試驗和漫長的審查週期，導致創新治療方法上市延遲。製造商在應對這些挑戰性流程的同時，投資回報的不確定性可能會阻礙潛在投資者，並減緩技術推廣的整體速度。這種監理負擔帶來的財務影響巨大。 《歐洲醫療技術》雜誌報告稱，到2025年，隨著合規標準的演變，醫療設備製造商將面臨與監管合規和再認證週期相關的成本增加50%。營運成本的急劇上升迫使企業將大量研發資金轉移到滿足行政要求。因此，原本可以用於開發下一代冷等離子體解決方案的資源被合規義務所消耗，導致產品平臺縮減，市場擴張速度放緩。

市場趨勢

攜帶式和手持式等離子體設備的開發正在從根本上改變冷等離子體療法的實施方式，將治療場所從集中控制的醫院設施轉移到門診和臨床環境。這一趨勢的特徵是高壓電源和氣體儲存裝置的小型化，使臨床醫生能夠直接在患者床邊或遠端地點進行等離子體治療。這種朝向行動化方向發展的產業轉型，得益於旨在將這些小型化技術推向全球商業化的巨額資金流入。例如，2025年7月，Adtec Healthcare宣布已獲得1,200萬美元的策略性資金籌措，以加速其下一代手持式冷等離子設備的開發並進入美國市場。這筆專款凸顯了該產業向靈活、以用戶為中心的系統轉型，從而將先進的感染控制與龐大的資本基礎設施脫鉤。同時，在向美容和皮膚科領域的拓展推動下，市場收入來源正在迅速多元化，超越傳統的治療適應症。隨著消費者越來越偏好恢復期短的能量型療程，冷等離子體作為一種非侵入式的活膚和組織緊緻療法正日益受到關注。該技術利用其刺激成纖維母細胞活性和膠原蛋白生成的能力，避免了通常與強效雷射治療相關的熱損傷。消費者對非手術矯正療法的濃厚興趣支撐了這一領域的商業性可行性。 Apyx Medical在2025年3月發布的報告顯示，2024年消費者對「皮膚鬆弛」的搜尋增加了168.7%，這項需求激增直接推動了基於等離子體的塑形平台的普及。隨著製造商將產品適應症與這些美容需求結合，市場正明顯轉向以生活方式為導向的醫療設備。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球醫療領域冷等離子市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依應用領域（創傷治療、外科手術、其他醫療用途）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美醫療保健產業冷等離子體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲醫療保健產業冷等離子體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區醫療保健產業冷等離子體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲醫療領域冷等離子體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美醫療領域冷等離子體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球醫療領域冷等離子市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Neoplas med GmbH
  • US Medical Innovations LLC
  • Terumo Medical Corp
  • Adtec Plasma Technology Co Ltd
  • Apyx Medical Corp
  • Nordson Corp
  • Europlasma NV
  • Terraplasma GmbH
  • Henniker Plasma
  • Smith & Nephew plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16339

The Global Cold Plasma in Healthcare Market is projected to grow from USD 2.59 Billion in 2025 to USD 5.33 Billion by 2031, exhibiting a 12.78% Compound Annual Growth Rate. Cold plasma in healthcare is characterized as a non-thermal, partially ionized gas produced at near-ambient temperatures, finding diverse medical applications in areas such as sterilization, chronic wound healing, and cancer therapy, all without causing thermal damage to viable tissues. The market's foundational support stems from the escalating demand for non-invasive treatment modalities and the urgent requirement for advanced infection control measures to combat antibiotic-resistant pathogens; notably, in 2025, approximately one in ten patients globally contracted a healthcare-associated infection, highlighting the critical industrial need for effective decontamination technologies like cold plasma.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.59 Billion
Market Size 2031USD 5.33 Billion
CAGR 2026-203112.78%
Fastest Growing SegmentWound Healing
Largest MarketNorth America

Market Driver

The escalating prevalence of chronic wounds and diabetic ulcers is a primary driver for market expansion, necessitating advanced therapies beyond conventional wound care. Cold plasma devices are increasingly employed to accelerate tissue regeneration and eliminate bacterial biofilms in non-healing lesions by generating reactive oxygen and nitrogen species. This demand is significantly fueled by the rising global burden of metabolic diseases, with roughly 589 million adults worldwide living with diabetes in 2025, a condition strongly linked to a high susceptibility to complex foot ulcers. The urgency for such alternative treatments is further amplified by the diminishing efficacy of standard antibiotics in wound management; the World Health Organization reported in October 2025 that antibiotic resistance had risen by over 40% in monitored pathogen-antibiotic combinations since 2018, emphasizing the industrial imperative for cold plasma technology's non-pharmaceutical bactericidal mechanisms. Concurrently, the market is experiencing substantial growth due to the emerging potential of cold plasma as a selective cancer treatment. Unlike traditional radiation or chemotherapy, cold atmospheric plasma can induce apoptosis in malignant cells through oxidative stress while leaving healthy tissue unharmed, representing a revolutionary approach for managing solid tumors. This clinical efficacy is beginning to manifest in tangible regulatory and trial successes; for instance, US Medical Innovations reported in May 2024 that phase I clinical trials for the FDA-cleared Canady Helios Cold Plasma System demonstrated a non-local recurrence rate of up to 80% in patients with advanced solid tumors. As research continues to validate these positive outcomes, the integration of plasma systems into oncological surgical protocols is anticipated to stimulate significant investment in advanced electrosurgical generators and probes.

Market Challenge

The stringent regulatory frameworks governing medical device approvals represent a significant impediment to the Global Cold Plasma in Healthcare Market. This challenge hinders market growth by establishing high barriers to entry that disproportionately impact small and medium-sized enterprises, which often spearhead plasma technology innovations. The intricate process of validating the safety and efficacy of partially ionized gas applications mandates capital-intensive clinical trials and protracted review periods, thereby delaying the commercial release of innovative therapies. As manufacturers navigate these arduous protocols, the uncertainty of return on investment can deter potential investors and slow the overall pace of technological adoption. The financial magnitude of this regulatory burden is substantial; MedTech Europe reported in 2025 that medical device manufacturers faced a 50% increase in costs associated with regulatory maintenance and re-certification cycles due to evolving compliance standards. This sharp rise in operational expenditure compels companies to redirect critical funds away from research and development to fulfill administrative requirements. Consequently, the market experiences constricted product pipelines and reduced expansion rates, as resources that could drive the next generation of cold plasma solutions are consumed by compliance obligations.

Market Trends

The development of portable and handheld plasma devices is fundamentally transforming the delivery of cold plasma therapies by shifting treatment from centralized hospital units to ambulatory and point-of-care settings. This trend is characterized by the miniaturization of high-voltage power supplies and gas reservoirs, enabling clinicians to administer plasma directly at a patient's bedside or in remote locations. The industrial drive towards mobility is underscored by significant capital inflows aimed at scaling these compact technologies for global commercialization; for example, Adtec Healthcare announced in July 2025 that it secured $12 million in strategic funding to accelerate the development and US market entry of its next-generation handheld cold plasma devices. This targeted financial support highlights the industry's pivot towards flexible, user-centric systems that decouple advanced infection control from heavy capital equipment infrastructure. Simultaneously, the expansion into aesthetic and cosmetic dermatology applications is rapidly diversifying the market's revenue streams beyond traditional therapeutic indications. Cold plasma is gaining traction as a non-invasive alternative for skin rejuvenation and tissue tightening, driven by growing consumer preference for energy-based procedures with minimal downtime. This application leverages the technology's ability to stimulate fibroblast activity and collagen production without the thermal injury typically associated with aggressive laser therapies. The commercial viability of this segment is emphasized by surging consumer interest in non-surgical corrections; Apyx Medical reported in March 2025 that consumer searches for "sagging skin" increased by 168.7% in 2024, a demand spike that directly supports the adoption of plasma-based body contouring platforms. As manufacturers align product indications with these cosmetic needs, the market is witnessing a distinct move towards lifestyle-oriented medical devices.

Key Market Players

  • Neoplas med GmbH
  • U.S. Medical Innovations LLC
  • Terumo Medical Corp
  • Adtec Plasma Technology Co Ltd
  • Apyx Medical Corp
  • Nordson Corp
  • Europlasma NV
  • Terraplasma GmbH
  • Henniker Plasma
  • Smith & Nephew plc

Report Scope

In this report, the Global Cold Plasma in Healthcare Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cold Plasma in Healthcare Market, By Application

  • Wound Healing
  • Surgical Application
  • Other Medical Applications

Cold Plasma in Healthcare Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cold Plasma in Healthcare Market.

Available Customizations:

Global Cold Plasma in Healthcare Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cold Plasma in Healthcare Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Wound Healing, Surgical Application, Other Medical Applications)
    • 5.2.2. By Region
    • 5.2.3. By Company (2025)
  • 5.3. Market Map

6. North America Cold Plasma in Healthcare Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cold Plasma in Healthcare Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
    • 6.3.2. Canada Cold Plasma in Healthcare Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
    • 6.3.3. Mexico Cold Plasma in Healthcare Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application

7. Europe Cold Plasma in Healthcare Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cold Plasma in Healthcare Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
    • 7.3.2. France Cold Plasma in Healthcare Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
    • 7.3.3. United Kingdom Cold Plasma in Healthcare Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
    • 7.3.4. Italy Cold Plasma in Healthcare Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
    • 7.3.5. Spain Cold Plasma in Healthcare Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application

8. Asia Pacific Cold Plasma in Healthcare Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cold Plasma in Healthcare Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
    • 8.3.2. India Cold Plasma in Healthcare Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
    • 8.3.3. Japan Cold Plasma in Healthcare Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
    • 8.3.4. South Korea Cold Plasma in Healthcare Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
    • 8.3.5. Australia Cold Plasma in Healthcare Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application

9. Middle East & Africa Cold Plasma in Healthcare Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cold Plasma in Healthcare Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
    • 9.3.2. UAE Cold Plasma in Healthcare Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
    • 9.3.3. South Africa Cold Plasma in Healthcare Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application

10. South America Cold Plasma in Healthcare Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cold Plasma in Healthcare Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
    • 10.3.2. Colombia Cold Plasma in Healthcare Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
    • 10.3.3. Argentina Cold Plasma in Healthcare Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cold Plasma in Healthcare Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Neoplas med GmbH
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. U.S. Medical Innovations LLC
  • 15.3. Terumo Medical Corp
  • 15.4. Adtec Plasma Technology Co Ltd
  • 15.5. Apyx Medical Corp
  • 15.6. Nordson Corp
  • 15.7. Europlasma NV
  • 15.8. Terraplasma GmbH
  • 15.9. Henniker Plasma
  • 15.10. Smith & Nephew plc

16. Strategic Recommendations

17. About Us & Disclaimer